Marsico Fabio, Cecere Milena, Parente Antonio, Paolillo Stefania, de Martino Fabiana, Dellegrottaglie Santo, Trimarco Bruno, Perrone Filardi Pasquale
Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini, 5, 80131, Naples, Italy.
IRCCS SDN, Istituto di Ricerca, Naples, Italy.
J Thromb Thrombolysis. 2017 Feb;43(2):139-148. doi: 10.1007/s11239-016-1421-9.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and predisposes to an increased risk of thromboembolic events. Patients affected by AF exhibit an increased risk of stroke compared with those in sinus rhythm, with the most common location of thrombi in the left atrial appendage. Until 2009, warfarin and other vitamin K antagonists were the only class of oral anticoagulants available. More recently, dabigatran, rivaroxaban, apixaban, and edoxaban have been approved by regulatory authorities for prevention of stroke in patients with non-valvular AF. Few data are available about the efficacy of novel oral anticoagulants for the treatment of left atrial and left atrial appendage thrombosis. Aim of this review is to summarize available evidence regarding the effectiveness of novel oral anticoagulants on left atrial appendage thrombosis.
心房颤动（AF）是最常见的持续性心律失常，易导致血栓栓塞事件风险增加。与窦性心律患者相比，AF患者发生中风的风险更高，血栓最常见的部位是左心耳。直到2009年，华法林和其他维生素K拮抗剂是仅有的一类可用的口服抗凝剂。最近，达比加群、利伐沙班、阿哌沙班和依度沙班已获监管机构批准用于预防非瓣膜性AF患者的中风。关于新型口服抗凝剂治疗左心房和左心耳血栓形成的疗效，目前可用的数据很少。本综述的目的是总结关于新型口服抗凝剂对左心耳血栓形成有效性的现有证据。
